RetagliptinAlternative Names: SP 2086
Latest Information Update: 05 May 2017
Price : $50 *
At a glance
- Originator Jiangsu Hengrui Medicine Co.
- Class Antihyperglycaemics; Carboxylic acids; Fluorobenzenes; Imidazoles; Pyrazines; Small molecules
- Mechanism of Action CD26 antigen inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preregistration Submission Withdrawal Type 2 diabetes mellitus
Most Recent Events
- 24 Jun 2018 Biomarkers information updated
- 04 Jul 2016 Jiangsu HengRui Medicine Co. plans a phase I pharmacokinetics trial in Healthy volunteers in China (PO) (NCT02826044)
- 01 Apr 2016 Jiangsu HengRui Medicine Co. initiates a phase I pharmacokinetics trial for Type-2 diabetes mellitus in China (PO) (NCT02822534)